Base de datos : MEDLINE
Búsqueda : C04.557.465.625.600.590.650.550.150 [Categoria DeCS]
Referencias encontradas : 611 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 62 va a la página                         

  1 / 611 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29324814
Autor:Topcagic J; Feldman R; Ghazalpour A; Swensen J; Gatalica Z; Vranic S
Dirección:Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina.
Título:Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
Fuente:PLoS One; 13(1):e0191244, 2018.
ISSN:1932-6203
País de publicación:United States
Idioma:eng
Resumen:Olfactory neuroblastoma (ONB) is a rare, locally aggressive, malignant neoplasm originating in the olfactory epithelium in the nasal vault. The recurrence rate of ONB remains high and there are no specific treatment guidelines for recurrent/metastatic ONBs. This study retrospectively evaluated 23 ONB samples profiled at Caris Life Sciences (Phoenix, Arizona) using DNA sequencing (Sanger/NGS [Illumina], n = 15) and gene fusions (Archer FusionPlex, n = 6), whole genome RNA microarray (HumanHT-12 v4 beadChip, Illumina, n = 4), gene copy number assays (chromogenic and fluorescent in situ hybridization), and immunohistochemistry. Mutations were detected in 63% ONBs including TP53, CTNNB1, EGFR, APC, cKIT, cMET, PDGFRA, CDH1, FH, and SMAD4 genes. Twenty-one genes were over-expressed and 19 genes under-expressed by microarray assay. Some of the upregulated genes included CD24, SCG2, and IGFBP-2. None of the cases harbored copy number variations of EGFR, HER2 and cMET genes, and no gene fusions were identified. Multiple protein biomarkers of potential response or resistance to classic chemotherapy drugs were identified, such as low ERCC1 [cisplatin sensitivity in 10/12], high TOPO1 [irinotecan sensitivity in 12/19], high TUBB3 [vincristine resistance in 13/14], and high MRP1 [multidrug resistance in 6/6 cases]. None of the cases (0/10) were positive for PD-L1 in tumor cells. Overexpression of pNTRK was observed in 67% (4/6) of the cases without underlying genetic alterations. Molecular alterations detected in our study (e.g., Wnt and cKIT/PDGFRA pathways) are potentially treatable using novel therapeutic approaches. Identified protein biomarkers of response or resistance to classic chemotherapy could be useful in optimizing existing chemotherapy treatment(s) in ONBs.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Biomarkers, Tumor); 0 (DNA, Neoplasm)


  2 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28399835
Autor:Xiong L; Zeng XL; Guo CK; Liu AW; Huang L
Dirección:Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi Province, 330006, China.
Título:Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients.
Fuente:BMC Cancer; 17(1):254, 2017 04 11.
ISSN:1471-2407
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: The standard treatment for esthesioneuroblastoma, a rare malignant nasal vault neoplasm, is not established. METHODS: We retrospectively assessed the clinicopathological features, prognostic factors and treatment methods for 187 patients with esthesioneuroblastoma treated in China between 1981 and 2015. Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method and log-rank tests. RESULTS: Twenty-three (12.3%), 48 (25.7%) and 113 (60.4%) patients had Kadish stage A, B and C esthesioneuroblastoma; 3 (1.6%) had unknown stage. Overall, 117 (62.6%) patients received surgery and combined radiotherapy with or without chemotherapy; 35 (18.7%) received radiotherapy with or without chemotherapy; 32 (17.1%) received surgery alone; and 3 (1.6%) received palliative treatment. Three-year OS and DFS for the entire cohort were 66.7% and 57.5%, respectively. Three-year OS for stage A, B and C were 91.3%, 91.2% and 49.5% (P < 0.0001). Three-year OS was 16.7% and 66.7% for patients with and without distant metastasis (P < 0.0001). Surgery and combined radiotherapy with or without chemotherapy led to better OS and DFS than other treatment modes (both P < 0.0001). Univariate and multivariate analysis showed distant metastasis (hazard ratio [HR] = 2.162, 95% confidence interval [CI] = 1.145, 4.082, P = 0.017) and not receiving a combined modality treatment (HR = 2.391, 95% CI = 1.356, 4.218, P = 0.003) were independent prognostic factors for poor OS and DFS. CONCLUSIONS: This study indicates surgery and combined radiotherapy may currently be the optimal treatment for esthesioneuroblastoma.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T


  3 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28349538
Autor:Ishii M; Bishop JA; Gallia GL
Dirección:Department of Otolaryngology-Head and Neck Surgery and Neurosurgery, Johns Hopkins University, Baltimore, Maryland, U.S.A.
Título:Assessment of frozen section margin analysis during olfactory neuroblastoma surgery.
Fuente:Laryngoscope; 127(8):1735-1741, 2017 Aug.
ISSN:1531-4995
País de publicación:United States
Idioma:eng
Resumen:OBJECTIVES: 1) assess the performance of the intraoperative frozen section procedure to correctly classify biopsies obtained during olfactory neuroblastoma (ONB) surgery; 2) define the relationship between posttest probabilities and pretest probabilities from frozen section analysis; and 3) review incorrectly classified specimens. STUDY DESIGN: Study of diagnostic accuracy. METHODS: We searched our institution's pathology database for patients who had ONB surgery between January 1, 2000 and November 16, 2012. We only included patients who had a definitive diagnosis of ONB prior to surgery and frozen sections obtained during surgery. All frozen sections in this study had corresponding permanent sections available to serve as a gold standard. This database was analyzed to obtain classification statistics. The confidence intervals for classification performance were obtained using the bootstrap sampling method. Confidence intervals for posttest probability curves were derived using the Taylor series expansion. Finally, we obtained and reviewed the slides from ambiguous or incorrect reads. RESULTS: A total of 459 specimens from 33 patients were analyzed. We found the following performance characteristics: sensitivity: 0.89 (0.81, 0.94); specificity: 0.96 (0.94, 0.98); accuracy: 0.95 (0.92, 0.96); likelihood ratio positive: 24.4 (14.5, 44.1); prevalence: 0.20 (0.17, 0.25); positive predictive value: 0.86 (0.78, 0.92); and negative predictive value: 0.97 (0.95, 0.99). Histopathologic review revealed that crush artifacts and inadequate specimen size were major sources of incorrect reads. CONCLUSION: We found frozen section assessment of ONB specimens to be an excellent tool for the assessment of intraoperative margins. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:1735-1741, 2017.
Tipo de publicación:JOURNAL ARTICLE


  4 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28348423
Autor:Pirrone C; Chiaravalli AM; Marando A; Conti A; Rainero A; Pistochini A; Lo Curto F; Pasquali F; Castelnuovo P; Capella C; Porta G
Dirección:University of Insubria, Department of Clinical and Experimental Medicine. cristina.pirrone@hotmail.it.
Título:OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas.
Fuente:Eur J Histochem; 61(1):2730, 2017 Feb 09.
ISSN:2038-8306
País de publicación:Italy
Idioma:eng
Resumen:OTX Homeobox genes are involved in embryonic morphogenesis and in the development of olfactory epithelium in adult. Mutations occurring in the OTX genes are reported to be associated to tumorigenisis in human. No reports correlate the expression of OTX genes and neoplasms of the nasal cavity. Thus, through immunohistochemical and Real-time PCR analysis we investigated OTX1 and OTX2 expression in the more frequent types of nasal and sinonasal tumours. Variable expression of both genes were found in normal sinonasal mucosa and in tumours. Interestingly, no expression of both OTX genes were detected in sinonasal intestinal-type adenocarcinomas; only OTX1 was found in non-intestinal-type adenocarcinomas and OTX2 was selectively expressed in olfactory neuroblastomas. In conclusion, OTX1 and OTX2 genes might have a role in the pathogenesis of different types of sinonasal neoplasms.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Biomarkers, Tumor); 0 (Neoplasm Proteins); 0 (OTX1 protein, human); 0 (OTX2 protein, human); 0 (Otx Transcription Factors)


  5 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28314402
Autor:Neel GS; Nagel TH; Hoxworth JM; Lal D
Dirección:Department of Otolaryngology-Head & Neck Surgery, Mayo Clinic, 5777 East Mayo Bouelvard, Phoenix, AZ 85054, USA.
Título:Management of Orbital Involvement in Sinonasal and Ventral Skull Base Malignancies.
Fuente:Otolaryngol Clin North Am; 50(2):347-364, 2017 Apr.
ISSN:1557-8259
País de publicación:United States
Idioma:eng
Resumen:The orbit may be frequently involved by sinonasal or ventral skull base malignancy. This involvement bodes a poorer prognosis for survival. Multimodality therapy with surgery and radiation therapy is usually attempted to optimize local control and overall survival. Oncologic surgical resection with negative margins is critical to local control and survival. In the past, any involvement of the orbit was deemed to necessitate orbital sacrifice. However, contemporary studies show that in carefully selected cases, orbital preservation does not adversely impact survival. In addition, novel reconstructive techniques can help minimize complications and optimize functional and aesthetic outcomes.
Tipo de publicación:JOURNAL ARTICLE; REVIEW; VIDEO-AUDIO MEDIA


  6 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28062086
Autor:Nakamura N; Zenda S; Tahara M; Okano S; Hayashi R; Hojo H; Hotta K; Kito S; Motegi A; Arahira S; Tachibana H; Akimoto T
Dirección:Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: naoknaka@east.ncc.go.jp.
Título:Proton beam therapy for olfactory neuroblastoma.
Fuente:Radiother Oncol; 122(3):368-372, 2017 Mar.
ISSN:1879-0887
País de publicación:Ireland
Idioma:eng
Resumen:PURPOSE: To clarify the efficacy and feasibility of proton beam therapy (PBT) for olfactory neuroblastoma (ONB). METHODS AND MATERIALS: We retrospectively reviewed 42 consecutive patients who received PBT with curative intent for ONB at National Cancer Center Hospital East from November 1999 to March 2012. RESULTS: Five patients (12%) had Kadish A disease, nine (21%) had Kadish B, and twenty-eight (67%) had Kadish C. All patients except one received a total dose of 65Gy (relative biological effectiveness: RBE) in 26 fractions. Twenty-four patients (57%) received induction and/or concurrent chemotherapy. The median follow-up for all eligible patients was 69months (7-186). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 100% and 80% for Kadish A, 86 and 65% for Kadish B, and 76% and 39% for Kadish C, respectively. The sites of the first progression were local in six patients (30%), regional in eight (40%), distant in two (10%), local and regional in two (10%), and local and distant in two (10%). Late adverse events of grade 3-4 were seen in six patients (ipsilateral visual impairment, 3; bilateral visual impairment, 1; liquorrhea, 1; cataract, 1). CONCLUSION: PBT was a safe and effective modality for ONB.
Tipo de publicación:JOURNAL ARTICLE


  7 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27917732
Autor:Schmidt C; Potter N; Porceddu S; Panizza B
Dirección:Department of Otolaryngology, Head and Neck Surgery,Princess Alexandra Hospital,Brisbane,Australia.
Título:Olfactory neuroblastoma: 14-year experience at an Australian tertiary centre and the role for longer-term surveillance.
Fuente:J Laryngol Otol; 131(S2):S29-S34, 2017 Jul.
ISSN:1748-5460
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Olfactory neuroblastoma is a rare sinonasal malignancy, with poorly defined treatment protocols. Management at a tertiary centre was retrospectively evaluated to inform future treatment and follow up. METHODS: Cases treated with curative intent (2000-2014) were included. Data were collected, and overall and disease-free survival rates were calculated. RESULTS: Eleven cases were identified, with a median follow up of 87 months. One patient was Kadish stage A, one was stage B, eight were stage C and one was stage D. The latter patient underwent chemoradiotherapy alone. The remaining patients proceeded to: endoscopic-assisted wide local excision (n = 2), anterior craniofacial resection (n = 4) or endoscopic craniofacial resection (n = 4). No patients had primary nodal disease or elective neck treatment. One patient had neoadjuvant chemoradiation. Six patients had post-operative radiotherapy; three received adjuvant chemotherapy. Two patients had late cervical node failure, and proceeded to neck dissection and post-operative radiotherapy. Two patients had late local recurrence. Ten-year overall and disease-free survival rates were 68.2 and 46.7 per cent, respectively. CONCLUSION: Longer-term follow up is supported given the incidence of late regional and local recurrence. Prophylactic treatment of cervical nodes in locally advanced disease is an area for further investigation.
Tipo de publicación:JOURNAL ARTICLE


  8 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27481043
Autor:Elkhatib AH; Soldatova L; Carrau RL; Hachem RA; Ditzel L; Campbell R; Prevedello DM; Prevedello L; Filho LF; Campbell RG
Dirección:Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Ohio, U.S.A.
Título:Role of F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma.
Fuente:Laryngoscope; 127(2):321-324, 2017 Feb.
ISSN:1531-4995
País de publicación:United States
Idioma:eng
Resumen:OBJECTIVES: The purpose of this study is to demonstrate the potential contribution of positron emission tomography (PET)/computed tomography (CT) to help differentiate olfactory neuroblastoma (ONB) from sinonasal undifferentiated carcinoma (SNUC). METHODS: Following approval by the institutional review board at the Wexner Medical Center at the Ohio State University, Columbus, Ohio, a pilot study with retrospective review of patients with biopsy-proven diagnosis of ONB s and SNUC s was conducted. Staging PET/CT scans were reviewed to document the maximum standardized uptake value (SUVmax). A statistical comparison of SUVmax was performed. RESULTS: We identified 13 patients (7 with ONBs and 6 with SNUCs) with mean age 60.2 years who had undergone staging F-18 fluorodeoxyglucose ( F-FDG) PET/CT of the primary tumor at the time of their diagnosis. Mean SUVmax was found to be five-fold higher in SNUC patients (35.63, range 10.8-77.9) than in ONB patients (7.24, range 4.6-10.7) (P ≤ 0.00169). CONCLUSION: Maximum standardized uptake value of F-FDG PET/CT can be used to initially discriminate between ONB and SNUC. This finding may prove helpful to guide diagnostic and treatment planning when the histopathologic diagnosis is inconclusive. LEVEL OF EVIDENCE: 4. Laryngoscope, 2016 127:321-324, 2017.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0Z5B2CJX4D (Fluorodeoxyglucose F18)


  9 / 611 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27938977
Autor:Belliveau MJ; Wang JC; Nijhawan N; Latta EK; Lee JM
Dirección:Department of Ophthalmology and Vision Sciences, St. Michael's Hospital, University of Toronto, Toronto, Ont.
Título:Staged endonasal-external resection of esthesioneuroblastoma involving the nasolacrimal duct and lacrimal sac.
Fuente:Can J Ophthalmol; 51(6):e173-e175, 2016 Dec.
ISSN:1715-3360
País de publicación:England
Idioma:eng
Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE


  10 / 611 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27806104
Autor:Zhang L; Niu K; Zhu K; Xia C; Yan J; Zhao W; Wei J; Duan M; Zheng G
Dirección:Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Título:Long-Term Prognostic Analysis after Endoscopic Endonasal Surgery for Olfactory Neuroblastoma: A Retrospective Study of 13 Cases.
Fuente:PLoS One; 11(11):e0166046, 2016.
ISSN:1932-6203
País de publicación:United States
Idioma:eng
Resumen:OBJECTIVES: To summarize the characteristics and long-term outcomes of olfactory neuroblastoma through the analysis of 13 cases in single institution, with the assessment of treatment modality, prognostic factors. METHOD: A retrospective study of thirteen cases diagnosed as olfactory neuroblastoma and underwent combined treatments during the period 2000-2010. Statistical analysis was performed to search for prognostic factors and compared different treatment modalities. RESULTS: 13 patients were enrolled in this study, including 8 male and 5 female, ranging from 15 to 69 (median 43) years old. One patient at stage A was only treated with endoscopic endonasal surgery (EES). Seven patients were treated with preoperative radiotherapy and EES, two with EES and postoperative radiotherapy, and the other three with combined radiotherapy and chemotherapy. The range of follow-up time varied from 23 to 116 months (median 65 months). The 5-year overall survival rate was 46.2% (6/13). To date, these thirteen patients have not suffered local recurrences while two patients had lymph node recurrences and one had distant metastasis in the bone marrow. In 13 patients, 61.5% were diagnosed as late T stage (T3/4), 69.2% late Kadish stage (C/D) and 53.8% were high Hyams grade (I/ II), which indicated poor prognosis. Related prognostic factors were the TNM stage (T stage P = 0.028, N stage P = 0.000, M stage P = 0.007), Kadish stage (P = 0.025) and treatment modality (P = 0.015). CONCLUSION: Late stage of TNM and Kadish staging system indicated a poor prognosis. Combined treatment modality, including endoscopic endonasal surgery, achieved a better outcome than non-surgical approach.
Tipo de publicación:JOURNAL ARTICLE



página 1 de 62 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud